"Clinical trials in Azerbaijan began in February 2021 ... Preliminary data from the first 20 participants shows antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases. The interim analysis of data has previously demonstrated a high safety profile for the combined use of the vaccines with no serious adverse effects or cases of coronavirus infection after vaccination," the RDIF said in a press release.
A memorandum of cooperation between Sputnik V developer Gamaleya Center, AstraZeneca, the RDIF and R-Pharm was signed in December 2020.
The document assumes cooperation in the development and implementation of a clinical research program to evaluate the combined use of one of the components of the Sputnik V vaccine and one of the components of the AZD1222 vaccine, developed by AstraZeneca in cooperation with the University of Oxford.